These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19939231)

  • 1. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.
    Frisardi V; Solfrizzi V; Imbimbo PB; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Seripa D; Pilotto A; Capurso A; Panza F
    Curr Alzheimer Res; 2010 Feb; 7(1):40-55. PubMed ID: 19939231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
    Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
    Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
    Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
    CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
    Imbimbo BP; Giardina GA
    Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Paris F; Santamato A; D'Onofrio G; Logroscino G; Pilotto A; Solfrizzi V
    Curr Alzheimer Res; 2011 Dec; 8(8):808-17. PubMed ID: 21592055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies.
    Christensen DD
    CNS Spectr; 2007 Feb; 12(2):113-6, 119-23. PubMed ID: 17277711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
    Abe K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.